<?xml version="1.0" encoding="UTF-8"?>
<ref id="tbed13734-bib-0023">
 <mixed-citation publication-type="journal" id="tbed13734-cit-0023">
  <string-name>
   <surname>Dong</surname>, 
   <given-names>W.</given-names>
  </string-name>, 
  <string-name>
   <surname>Xie</surname>, 
   <given-names>W.</given-names>
  </string-name>, 
  <string-name>
   <surname>Liu</surname>, 
   <given-names>Y.</given-names>
  </string-name>, 
  <string-name>
   <surname>Sui</surname>, 
   <given-names>B.</given-names>
  </string-name>, 
  <string-name>
   <surname>Zhang</surname>, 
   <given-names>H.</given-names>
  </string-name>, 
  <string-name>
   <surname>Liu</surname>, 
   <given-names>L.</given-names>
  </string-name>, … 
  <string-name>
   <surname>Peng</surname>, 
   <given-names>G.</given-names>
  </string-name> (
  <year>2020</year>). 
  <article-title>Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen‐activated protein kinase pathways</article-title>. 
  <source xml:lang="en">Antiviral Research</source>, 
  <volume>173</volume>, 
  <fpage>104651</fpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104651</pub-id>
  <pub-id pub-id-type="pmid">31751591</pub-id>
 </mixed-citation>
</ref>
